237 related articles for article (PubMed ID: 37968119)
1. Alzheimer's Targeted Treatments: Focus on Amyloid and Inflammation.
Iwatsubo T; Irizarry MC; Lewcock JW; Carrillo MC
J Neurosci; 2023 Nov; 43(47):7894-7898. PubMed ID: 37968119
[TBL] [Abstract][Full Text] [Related]
2. A Recent Update on Pathophysiology and Therapeutic Interventions of Alzheimer's Disease.
Kashif M; Sivaprakasam P; Vijendra P; Waseem M; Pandurangan AK
Curr Pharm Des; 2023; 29(43):3428-3441. PubMed ID: 38038007
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
Parums DV
Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
[TBL] [Abstract][Full Text] [Related]
4. Emerging amyloid and tau targeting treatments for Alzheimer's disease.
Khan A; Corbett A; Ballard C
Expert Rev Neurother; 2017 Jul; 17(7):697-711. PubMed ID: 28490214
[TBL] [Abstract][Full Text] [Related]
5. The Single Toxin Origin of Alzheimer's Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention.
Tolar M; Hey JA; Power A; Abushakra S
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473975
[TBL] [Abstract][Full Text] [Related]
6. Novel disease-modifying therapies for Alzheimer's disease.
Jiang T; Yu JT; Tan L
J Alzheimers Dis; 2012; 31(3):475-92. PubMed ID: 22669013
[TBL] [Abstract][Full Text] [Related]
7. Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.
Golde TE
Neurotherapeutics; 2022 Jan; 19(1):209-227. PubMed ID: 35229269
[TBL] [Abstract][Full Text] [Related]
8. The past, present, and future of disease-modifying therapies for Alzheimer's disease.
Suzuki K; Iwata A; Iwatsubo T
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(10):757-771. PubMed ID: 29225305
[TBL] [Abstract][Full Text] [Related]
9. Targeting Novel microRNAs in Developing Novel Alzheimer's Disease Treatments.
Seyedaghamiri F; Rajabi M; Mohaddes G
Neurochem Res; 2023 Jan; 48(1):26-38. PubMed ID: 36048350
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
11. Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration.
Lim CH; Kaur P; Teo E; Lam VYM; Zhu F; Kibat C; Gruber J; Mathuru AS; Tolwinski NS
Elife; 2020 Mar; 9():. PubMed ID: 32228858
[TBL] [Abstract][Full Text] [Related]
12. Progress in the development of new drugs in Alzheimer's disease.
Piau A; Nourhashémi F; Hein C; Caillaud C; Vellas B
J Nutr Health Aging; 2011 Jan; 15(1):45-57. PubMed ID: 21267520
[TBL] [Abstract][Full Text] [Related]
13. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
Kalra J; Khan A
Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
[TBL] [Abstract][Full Text] [Related]
14. The Alzheimer's disease drug development landscape.
van Bokhoven P; de Wilde A; Vermunt L; Leferink PS; Heetveld S; Cummings J; Scheltens P; Vijverberg EGB
Alzheimers Res Ther; 2021 Nov; 13(1):186. PubMed ID: 34763720
[TBL] [Abstract][Full Text] [Related]
15. New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer's disease.
Zhang F; Zhong RJ; Cheng C; Li S; Le WD
Acta Pharmacol Sin; 2021 Sep; 42(9):1382-1389. PubMed ID: 33268824
[TBL] [Abstract][Full Text] [Related]
16. Recent Progress Towards Vaccines and Antibody-based Therapies Against Alzheimer's Disease.
Ji W; Gong B; Jin H; Chen X; Li P; Cheng W; Zhao Y; He B; Zhuang J; Gao J; Yin Y
Mini Rev Med Chem; 2021; 21(19):3062-3072. PubMed ID: 34353254
[TBL] [Abstract][Full Text] [Related]
17. Discontinued disease-modifying therapies for Alzheimer's disease: status and future perspectives.
Imbimbo BP; Lozupone M; Watling M; Panza F
Expert Opin Investig Drugs; 2020 Sep; 29(9):919-933. PubMed ID: 32657175
[TBL] [Abstract][Full Text] [Related]
18. Tau Protein Aggregation in Alzheimer's Disease: Recent Advances in the Development of Novel Therapeutic Agents.
Monteiro KLC; Alcântara MGDS; de Aquino TM; da Silva-Júnior EF
Curr Pharm Des; 2020; 26(15):1682-1692. PubMed ID: 32286939
[TBL] [Abstract][Full Text] [Related]
19. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.
Nicoll JAR; Buckland GR; Harrison CH; Page A; Harris S; Love S; Neal JW; Holmes C; Boche D
Brain; 2019 Jul; 142(7):2113-2126. PubMed ID: 31157360
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies.
Zetterberg H; Bendlin BB
Mol Psychiatry; 2021 Jan; 26(1):296-308. PubMed ID: 32251378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
